Skip to main content
    E

    Embecta Corp (EMBC)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $6.45
    +0.27 (+4.37%)

    Market Cap: $349.87M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    94%(16/17)
    Avg Surprise
    +43.76%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.48
    Range$0.47 - $0.50
    4 analysts
    Revenue Consensus
    $276M
    Range$275M - $277M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.49
    Range$0.39 - $0.67
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.49+0.7%
    60d ago$0.48+2.8%
    30d ago$0.48+2.8%
    7d ago$0.48+2.8%
    Current$0.49
    Revenue Consensus
    $268M
    Range$265M - $274M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.49---
    Sep 26EST
    		-$0.48---
    Jun 26
    Reported Aug 7
    		$0.56$0.26+115.38%Beat-50.0%
    Mar 26
    Reported May 5
    		$0.27$0.42-35.71%Miss-61.4%
    Dec 25
    Reported Feb 5
    		$0.71$0.67+5.97%Beat+9.2%
    Sep 25
    Reported Nov 25
    		$0.50$0.46+8.70%Beat+11.1%
    Jun 25
    Reported Aug 8
    		$1.12$0.78+43.59%Beat+51.4%
    Mar 25
    Reported May 9
    		$0.70$0.59+18.64%Beat+4.5%
    Dec 24
    Reported Feb 6
    		$0.65$0.44+47.73%Beat+6.6%
    Sep 24
    Reported Nov 26
    		$0.45$0.36+25.00%Beat-23.7%
    Jun 24
    Reported Aug 9
    		$0.74$0.46+60.87%Beat+7.2%
    Mar 24
    Reported May 9
    		$0.67$0.40+67.50%Beat-10.7%
    Dec 23
    Reported Feb 9
    		$0.61$0.46+32.61%Beat-36.5%
    Sep 23
    Reported Nov 21
    		$0.59$0.40+47.50%Beat-50.0%
    Jun 23
    Reported Aug 8
    		$0.69$0.46+50.00%Beat-43.0%
    Mar 23
    Reported May 12
    		$0.75$0.48+56.25%Beat-45.7%
    Dec 22
    Reported Feb 14
    		$0.96$0.52+84.62%Beat-86.6%
    Sep 22
    Reported Dec 20
    		$1.18$0.67+76.12%Beat-
    Jun 22
    Reported Aug 15
    		$1.21$0.87+39.08%Beat-
    Mar 22
    Reported May 13
    		$1.38N/AN/ABeat-
    Dec 21
    Reported Mar 16
    		$7.17$0.00N/ABeat-

    Dividends

    Dividend Metrics

    Forward Yield0.62%
    Forward Annual Dividend$0.04
    Payout Ratio20.72%
    FrequencyQuarterly
    Pay MonthsMar, Jun, Sep, Dec
    EMBC dividend history and ex-dividend datesRun EMBC in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio3.16EV/EBITDA5.61x
    Price/FCF2.22xFCF Yield45.04%
    Profitability
    Profit Margin8.59%Operating Margin23.70%
    ROE0.00%ROIC18.42%
    Financial Health
    Debt/Equity-2.37xInterest CoverageN/A
    Current Ratio1.68xQuick Ratio1.17x
    Trading Statistics
    Beta0.83Avg Volume1.02M
    52-Week High$14.4352-Week Low$2.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.96
    SMA 20$5.80
    SMA 50$5.37
    SMA 200$6.71
    EMA 10$6.02
    EMA 20$5.82
    EMA 50$5.36
    EMA 200$6.54

    MACD

    Line: 0.26Signal: 0.23Hist: 0.03

    ADX

    ADX: 28.8+DI: 30.5-DI: 11.6

    Aroon & PSAR

    Aroon Up100.0
    Aroon DownN/A
    PSAR$5.77

    Bollinger Bands

    Upper Band$6.37
    Lower Band$5.24
    %B Position1953%(Upper)
    Band Width1.07

    RSI (14-Day)

    Neutral
    69.9

    Momentum Oscillators

    Stoch %K91.3
    Stoch %D82.9
    Williams %R-11.9
    ROC (10d)11.4%
    Momentum0.66
    CCI (20d)203.8
    MFI (14d)62.4

    Volatility Measures

    ATR (14d)$0.29(4.5%)
    StdDev (20d)0.28
    Hist Vol43.6%(High)

    Volume Flow

    VWAP$6.41
    OBV9.4M
    AD Line-263.0M
    CMF (20d)0.158

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio0.9x
    VWMA (20d)$5.74

    Pivot Points

    R3$6.39
    R2$6.32
    R1$6.25
    Pivot Point$6.18
    S1$6.11
    S2$6.04
    S3$5.97

    Advanced Oscillators

    TSI26.76
    Ultimate Osc48.3
    KST130.05

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$271.70M$221.80M$261.20M$264.00M$295.50M$259.00M$261.90M$286.10M$272.50M$287.20M$277.30M$281.90M
    Cost of Revenue$118.40M$94.00M$99.50M$105.50M$98.40M$94.90M$104.80M$112.30M$82.40M$101.80M$91.40M$100.10M
    Gross Profit$153.30M$127.80M$161.70M$158.50M$197.10M$164.10M$157.10M$173.80M$190.10M$185.40M$185.90M$181.80M
    Operating Expenses$104.60M$92.80M$78.40M$102.00M$103.10M$101.20M$128.40M$147.60M$134.20M$146.20M$140.40M$156.00M
    R&D$5.60M$5.40M$4.60M$4.60M$4.40M$8.00M$20.30M$19.80M$20.40M$18.40M$20.20M$23.60M
    SG&A$78.60M$76.20M$77.60M$97.40M$84.40M$79.60M$81.10M$127.80M$113.80M$127.80M$120.20M$129.90M
    Operating Income$48.70M$35.00M$83.30M$56.50M$94.00M$62.90M$28.70M$26.20M$55.90M$39.20M$45.50M$25.80M
    Interest Income$-23,900,000$-22,600,000$-24,100,000$-26,100,000$-26,600,000$-26,700,000$-27,900,000$-29,000,000$-27,800,000$-27,800,000$-27,700,000$-27,600,000
    Interest Expense$21.10M$25.50M$24.40M$27.50M$21.80M$27.10M$29.40M$33.20M$28.90M$29.30M$31.20M$20.80M
    Income Before Tax$27.60M$9.50M$58.90M$29.00M$72.20M$35.80M$-700,000$-7,000,000$27.00M$9.90M$14.30M$5.00M
    Income Tax Expense$6.50M$13.60M$14.80M$2.60M$26.70M$12.30M$-700,000$-21,600,000$12.30M$-19,000,000$-5,800,000$-1,000,000
    Net Income$21.10M$-4,100,000$44.10M$26.40M$45.50M$23.50M$0$14.60M$14.70M$28.90M$20.10M$6.00M
    EBITDA$68.00M$46.80M$97.80M$73.40M$113.00M$76.20M$41.20M$36.10M$67.50M$49.50M$52.80M$43.50M
    EBIT$51.50M$32.10M$83.00M$55.10M$98.80M$62.50M$27.20M$22.00M$54.80M$37.70M$42.00M$32.60M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EMBC

    News

    The Technical Signals Behind (EMBC) That Institutions Follow

    The article analyzes Embecta Corp. (NASDAQ: EMBC) using AI models, highlighting strong near and mid-term sentiment but a weak long-term outlook. It identifies compelling upside potential due to the absence of resistance...

    Stock Traders Daily•10/8/26•Neutral

    Embecta Corp. (EMBC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

    Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Embecta Corp. (EMBC) regarding potential corporate wrongdoing. The firm is encouraging Embecta shareholders who purchased securities before November...

    ACCESS Newswire•9/29/26•Bearish

    EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION

    Bernstein Liebhard LLP has announced an investigation into potential breaches of fiduciary duty by directors and officers of Embecta Corp. (NASDAQ...

    GlobeNewswire•9/23/26•Bearish

    EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

    Bernstein Liebhard LLP has announced an investigation into Embecta Corp. (NASDAQ: EMBC) regarding potential breaches of fiduciary duty by its directors and officers. The firm is seeking to determine if the company's...

    Supply Chain Digital•9/22/26•Bearish

    Bronstein, Gewirtz & Grossman, LLC Encourages Embecta Corp. (EMBC) Investors to Inquire about Securities Investigation

    Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Embecta Corp. (NASDAQ:EMBC) securities who bought prior to November 25, 2026...

    The National Law Review•9/22/26•Bearish

    EMBC Valuation and Fair Value

    P/E
    3.2x
    EV/EBITDA
    5.6x
    P/FCF
    2.2x
    P/B
    -0.6x
    See GNG's fair value

    EMBC Profitability: Margins, ROIC and FCF

    Gross margin
    59.0%
    Operating margin
    23.7%
    Net margin
    8.6%
    ROIC
    18.4%
    ROE
    0.0%
    FCF margin
    16.2%
    FCF yield
    45.0%

    EMBC Competitors

    CompanyTicker
    Kyverna Therapeutics, Inc. Common StockKYTX
    Opus Genetics, Inc.IRD
    Emergent Biosolutions IncEBS
    Orchestra BioMed Holdings Inc.OBIO
    Fennec Pharmaceuticals IncFENC
    Semler Scientific IncSMLR
    Galectin Therapeutics IncGALT
    Enanta Pharmaceuticals IncENTA

    Sector: Healthcare

    EMBC Analyst Ratings

    Consensus
    Sell
    Analysts
    4
    Strong Buy
    0
    Buy
    0
    Hold
    3
    Sell
    0
    Strong Sell
    1

    EMBC Bull Case vs Bear Case

    Bull case

    • EMBC earns an 18.4% return on invested capital.
    • EMBC converts 16.2% of revenue into free cash flow.
    • EMBC beat EPS estimates in 87.5% of its last 8 reported quarters.

    Bear case

    • EMBC's quarterly revenue changed -8.1% year over year.

    EMBC Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    28.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.48

    EMBC Dividend

    Forward yield
    0.6%
    Payout ratio
    20.7%
    Pay months
    Mar, Jun, Sep, Dec
    EMBC dividend history

    Frequently Asked Questions About EMBC

    What is EMBC's current dividend yield?

    Embecta Corp (EMBC) has a forward dividend yield of 0.62%.

    Does EMBC pay dividends?

    Yes, Embecta Corp pays dividends with a forward dividend yield of 0.62%.

    What is EMBC's P/E ratio?

    Embecta Corp has a price-to-earnings (P/E) ratio of 3.16.

    What is EMBC's market cap?

    Embecta Corp (EMBC) has a market capitalization of $349.87M with a current stock price of $6.45.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In